Initiated Buy X

BNTX BioNTech

Citigroup

$145

Initiated Buy X

BNTX BioNTech

Truist

$172

Initiated Overweight X

BNTX BioNTech

Wells Fargo

$170

Reiterated Outperform X

BNTX BioNTech

BMO Capital Markets

Initiated Buy X

BNTX BioNTech

Berenberg

$130

Upgrades In-line Outperform X

BNTX BioNTech

Evercore ISI

$110 $125

Upgrades Neutral Buy X

BNTX BioNTech

Goldman

$90 $137

Upgrades Eq-Weight Overweight X

BNTX BioNTech

Morgan Stanley

$93 $145

Upgrades Hold Buy X

BNTX BioNTech

Jefferies

$96 $150

Upgrades Underweight Neutral X

BNTX BioNTech

JP Morgan

$91 $125

Upgrades Hold Buy X

BNTX BioNTech

Deutsche Bank

$95

Initiated In-line X

BNTX BioNTech

Evercore ISI

$100

Initiated Outperform X

BNTX BioNTech

BMO Capital Markets

$127

Initiated Perform X

BNTX BioNTech

Oppenheimer

Downgrades Neutral Underweight X

BNTX BioNTech

JP Morgan

$106 $99

Downgrades Buy Hold X

BNTX BioNTech

HSBC Securities

$124 $111

Initiated Buy X

BNTX BioNTech

HSBC Securities

$124

Upgrades Neutral Buy X

BNTX BioNTech

Redburn

$165 $170

Upgrades Neutral Buy X

BNTX BioNTech

BofA Securities

$239

Initiated Market Perform X

BNTX BioNTech

Cowen

$177

Upgrades Mkt Perform Outperform X

BNTX BioNTech

SVB Leerink

Resumed Buy X

BNTX BioNTech

Canaccord Genuity

$192

BNTX  BioNTech SE

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer. It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase 1a/1b clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 to treat solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II clinical trial to treat solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase II clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.